TWOMEY CHRISTOPHER J 4

What Happened

• Christopher J. Twomey, a director of Bionano Genomics, was granted a derivative award of 9,149 shares on 2026-05-14. The reported acquisition price is $0.00 per share (total reported value $0), filed on the same date. This is a compensatory equity award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Transaction type: Grant/Award (A); Reported price: $0.00 per share; Total reported value: $0.
• Shares owned after the transaction: Not specified in the provided filing.
• Vesting/conditions (Footnote F1): Shares vest in equal monthly installments over 12 months following the grant, will be fully vested by the company’s next annual stockholder meeting if service continues, and will vest in full upon a Change of Control. Vesting requires the option holder’s Continuous Service as defined in the 2018 equity incentive plan.
• Filing timeliness: Reported on the same date as the transaction (no late filing indicated).

Context

• This was a compensatory award to a director (common for board compensation). It is neither a market purchase (which some investors view as bullish) nor a sale. The award is a derivative grant (likely RSUs or restricted stock-type award) with standard time- and event-based vesting conditions.